Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

FDA to reconsider decision barring compounded versions of Lilly weight loss drug

Eli Lilly stock has jumped 200% over the past two years.

Warning: This Skyrocketing Stock Has a Hidden Risk

Eli Lilly (LLY) reachead $910.69 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Novo Nordisk

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

2 No-Brainer Dividend Growth Stocks to Buy Right Now

Novartis

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?

NVS or LLY: Which Is the Better Value Stock Right Now?

Allstate

Zebra Technologies

S&P 500 earnings season is kicking off. And some companies are expected to put up some huge numbers — even bigger than Nvidia

8 Stocks Poised To Report Nvidia-Beating Profit Growth Any Day Now

Eli Lilly's (LLY, Financial) stock experienced a notable movement, rising 1.71% to a price of $913.72. This surge was driven by the Congressional Budget Office (CBO) report on the potential impact if Medicare were to cover anti-obesity medications, including Eli Lilly's weight loss drug, Zepbound.

LLY Stock Rises on Congressional Budget Office Report

The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.

Why Eli Lilly Was Such a Healthy Stock Today

Combination of Qinotto's novel blood brain barrier platform and Lilly's therapeutic expertise could boost the delivery of large molecule therapeutics to the brain Combination of Qinotto's novel blood brain barrier platform and Lilly's therapeutic expertise could boost the delivery of large molecule therapeutics to the brain

Qinotto and Lilly Enter Research Collaboration and License Agreement

Growth for its GLP-1 weight loss drugs continues to be robust.

With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?

AstraZeneca

Bayer AG

Pfizer

Sanofi

Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

The Outsourcing Facilities Association, representing companies producing generic versions of Eli Lilly's (LLY, Financial) weight loss drug, has filed a lawsuit against the U.S. Food and Drug Administration (FDA) in a Texas federal court. The group claims that the FDA's decision to remove Eli Lilly's drug from the shortage list was "arbitrary, capricious, and unlawful.

LLY: Legal Battle Over FDA's Decision on Eli Lilly's Weight Loss Drug

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

Billion-Dollar News for Eli Lilly Stock Investors

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly's blockbuster weight loss and diabetes drugs from its shortage list last week, a move expected to curtail compounding facilities' ability to sell their own versions of the drugs.

Compounding group sues FDA for removing Lilly's weight loss drug from shortage list

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

BioAge Labs Inc

One of these businesses is a risky play, but the other is very likely to succeed.

2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now

Regeneron Pharmaceuticals

Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to muscle loss, respectively. In response, Regeneron (REGN) is researching a new drug aimed at mitigating muscle loss caused by weight loss medications.

Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)

Abbott Labs

UnitedHealth Group

Investors can find market-trouncing blue chip stocks in the healthcare industry.

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades

Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.

Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know

Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.

Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant

Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Eli Lilly (LLY) This Year?

England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of a three-year plan, UK's drugs cost regulator said on Thursday.

England's NHS to offer Lilly's weight-loss drugs to some patients

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.

Eli Lilly's weight-loss and diabetes drugs are no longer in shortage, says FDA

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

AbbVie

Merck

The pharmaceutical industry plays a crucial role in most of our everyday lives.

News for Eli Lilly Stock (LLY)